S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NASDAQ:AKRX - Akorn Stock Price, Forecast & News

$1.44
+0.02 (+1.41 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$1.37
Now: $1.44
$1.45
50-Day Range
$1.25
MA: $1.42
$1.72
52-Week Range
$1.19
Now: $1.44
$5.46
Volume2.41 million shs
Average Volume2.65 million shs
Market Capitalization$181.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
CUSIP00972810
CIK3116
Phone847-279-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$694.02 million
Cash Flow$0.36 per share
Book Value$3.54 per share

Profitability

Net Income$-401,910,000.00

Miscellaneous

Employees2,191
Market Cap$181.66 million
Next Earnings DateN/A
OptionableOptionable

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.


Akorn (NASDAQ:AKRX) Frequently Asked Questions

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.06. The business had revenue of $176.24 million for the quarter, compared to the consensus estimate of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The business's revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.06) EPS. View Akorn's Earnings History.

What price target have analysts set for AKRX?

3 equities research analysts have issued twelve-month price targets for Akorn's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Akorn's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 293.5% from the stock's current price. View Analyst Price Targets for Akorn.

What is the consensus analysts' recommendation for Akorn?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

Has Akorn been receiving favorable news coverage?

Media headlines about AKRX stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a news impact score of -4.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Akorn.

Are investors shorting Akorn?

Akorn saw a decline in short interest in January. As of January 15th, there was short interest totalling 5,820,000 shares, a decline of 31.6% from the December 31st total of 8,510,000 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is presently 2.5 days. Approximately 6.1% of the shares of the company are sold short. View Akorn's Current Options Chain.

Who are some of Akorn's key competitors?

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Who are Akorn's key executives?

Akorn's management team includes the folowing people:
  • Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
  • Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Bruce Kutinsky, Consultant (Age 53)
  • Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

Who are Akorn's major shareholders?

Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (8.38%), Canyon Capital Advisors LLC (3.96%), State Street Corp (2.67%), Geode Capital Management LLC (1.51%), Connor Clark & Lunn Investment Management Ltd. (1.03%) and Maverick Capital Ltd. (0.98%). Company insiders that own Akorn stock include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

Which major investors are selling Akorn stock?

AKRX stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Spark Investment Management LLC, Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Akorn.

Which major investors are buying Akorn stock?

AKRX stock was acquired by a variety of institutional investors in the last quarter, including Canyon Capital Advisors LLC, Maverick Capital Ltd., Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace North America L.P., Geode Capital Management LLC, Oxford Asset Management LLP and Gabelli Funds LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

How do I buy shares of Akorn?

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akorn's stock price today?

One share of AKRX stock can currently be purchased for approximately $1.44.

How big of a company is Akorn?

Akorn has a market capitalization of $181.66 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

What is Akorn's official website?

The official website for Akorn is http://www.akorn.com/.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]


MarketBeat Community Rating for Akorn (NASDAQ AKRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  549 (Vote Outperform)
Underperform Votes:  478 (Vote Underperform)
Total Votes:  1,027
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel